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A B S T R A C TObjective: To review published studies of Burden of Disease (BOD)
performed in the Asia-Pacific (AP) region. Method: Overlapping strat-
egy of searching four electronic databases was used to identify studies
of BOD published during 1993-2009. The quality of identified studies
was assessed according to the categories of burden reflected and
scope of BOD information included. Chronological and regional
distributions of research output were analyzed. Results: Among 524
articles identified for review, 27.7% (n¼145) were classified as com-
plete summary measures as being most informative BOD studies from
health policy maker’s perspective and 72.3% (n¼379) as using only
partial measures. Although an increasing trend of publication of BOD
articles was observed, the quantity of publication was notsee front matter Copyright & 2013, International
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acy, University of Newcastle, Callaghan, NSW 23commensurate with the number of diseases, especially for researches
using summary measures. Unbalance of research output of BOD among
different diseases areas and selected countries/regions was observed.
Conclusion: The paucity of specific studies in AP region needs to be
addressed. Furthermore, in order to improve the quality of research, a
clear definition of BOD study and a uniform template for the research
method from health policy-makers’ perspective would be necessary.
Keywords: Asia-Pacific, burden of disease, cost-of-illness, research
output.
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The Asia-Pacific (AP) region is a diverse area that encompasses
developed economies, such as Australia, Japan and Singapore,
emerging economy countries like India and China, in which most
of the population in the world reside, as well as poor and under-
developed countries. Likewise, the health-systems in these AP
countries are also diverse, but like other countries in Europe or
North America, most of them are confronting similar challenges
in delivering health care to their respective populations, namely:
increasing health-care expenses driven by expanding aging
population, increasing prevalence of chronic diseases and the
need to incorporate costly new health technologies into the
health care system. Given the demand and requirement to keep
a balance between efficacy and cost containment to ensure that
the available health resources are used in a cost-effective man-
ner, evidence-based decision-making are gradually and increas-
ingly accepted by AP countries in support of decision in
formulating and funding of health policies and programs [1,2].
In the process of making the decision about which programs
or interventions should be funded from the public purse, theo-
retically at least three criteria should be considered. These arethe comparative efficacy and safety of the new technologies to
existing treatments, the cost-effectiveness index, and the burden
of disease (BOD). Fundamentally, the decision rule is that only
health programs or health technologies (including new drugs,
diagnostics, etc.) considered being cost-effective and producing
positive net health benefits for the populations should be funded
by public finance. However, to add complexity to the issue, due to
the fact that resources are limited, not all potentially cost-
effective services can be funded. Priorities must be made in
allocating scarce resources and the new technologies or pro-
grams that can tackle diseases or disorders that inflict the greater
burden to society would naturally be given higher priorities.
Consequently, Burden of Disease (BOD) study with its objectives
of quantifying the burden imposed by the disease or disorder can
contribute to good decision making by helping priority setting for
health planning, public health programs, research and develop-
ment, as well as professional manpower training [3]. Further-
more, the results of studies of BOD can be incorporated into cost-
effectiveness analyses when evaluating affordability of health
interventions [4]. In addition, as a common currency, BOD results
can also be used as an indicator of overall health status at the
population level and compare efficiency of health care systemSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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study of BOD in one country can serve as a benchmark or
reference point for other countries.
Normally when talking about burden incurred by a disease, it
refers to three aspects: epidemiological burden, economic burden
and humanistic burden. The scope of BOD can be either broad or
narrow depending on the perspectives adopted, such as the
burden to the patients, to the health service provider, to the
payer and to society. In addition, a number of approaches and
indicators are used to assess the BOD. From the policy makers’
perspective, however, indicators integrating as much information
as possible that potentially highlight areas of greatest possible
health gain and resource consumption are more contributive to
decision making. Indeed, the evidence from Gross et al. in the
United States showed this preference of policy makers when
considering the relationship between disease-specific funding at
National Institute of Health with several measures [8].
In fact, public health specialists have monitored the burden of
some diseases for many decades with epidemiology parameters
such as prevalence, incidence and mortality etc. [9–11]. Epide-
miologic data can answer the question, ‘‘How big is the health
problem?’’ in terms of number of people affected and the
associated mortality (if applicable) in people afflicted with the
disease or disorder in a specific country or district. It cannot
reflect explicitly the magnitude of resource consumption and
quality of life loss, caused not only by fatal effect but also by non-
fatal effect of disease.
In early 1990s the Global Burden of Disease (GBD) Study was
commissioned by the World Bank and co-sponsored by World
Health Organization, in which Disability Adjusted Life Years
(DALY) was adopted as a summary indicator [3]. This composite
indicator combines the mortality and quality of life or morbidity
data and gives a more comprehensive estimation of BOD. The
result of 1990 GBD study revealed many previously under-
appreciated and unmeasured burden when measured by mortal-
ity alone, for example mental disorders and hearing loss, which
may cause considerable health impairment but no or few direct
deaths [3]. In addition, to express the burden of disease in terms
of both premature mortality and morbidity, various indicators
besides DALY have been compiled and adopted to measure BOD,
such as, Disability-Adjusted Life Expectancy (DALE), Disability-
Free Life Expectancy (DFLE), Health Adjusted Life Expectancy
(HALE) and Years of Healthy Life (YHL) [12–15]. Nevertheless, in
these summary humanistic burden measures, epidemiological
parameters are inputted to compute the outcome on a
population level.
Another commonly used approach to ascertain the burden of
disease is conducting a cost-of-illness study. The cost-of-illness
(COI) analysis, first clearly spelled out by the health economist,
Dr. Dorothy Rice, has been widely accepted as an effective
measure of BOD, especially the economic burden [16]. In essence,
COI study can translate simple descriptive epidemiology param-
eters into a measure of resource use and productivity loss in
monetary terms. Normally, economic costs of disease are divided
into direct, indirect and intangible costs. Direct costs are defined
as the cost of all resources associated with the provision of an
intervention or treatment for an illness. Indirect costs involve the
costs that result from the loss of productivity because of illness
or death. Intangible costs include the costs of pain, suffering,
anxiety, or fatigue that occur because of an illness or the treat-
ment of an illness. By capturing all these costs, COI not only
grasps the direct economic burden incurred by disease, but also
takes the economic effect of morbidity and mortality into
account from social perspective.
Since the first publication of GBD appeared in World Develop-
ment Report 1993: Investing in Health [17], many organizations
and several countries became interested in applying the resultsof BOD and combining it with cost-effectiveness evaluation to
better inform health policy [18–20]. Considering that health
service research activity should reflect the relative interest in
application of relevant information into decision-making proc-
ess, the aim of the current study is to review the more recent
output of BOD studies published in scientific journals from the AP
region, where health economics and outcomes research are
increasingly gaining interest [1]. This analysis will showcase the
current status of BOD research in this region and whether there
are sufficient studies of acceptable quality being performed and
published in the public domain to support the need of policy
makers in the AP region.Methods
Data source
Electronic literature databases searched were Medline, EMBASE,
EconLit and Cochrane Library. Overlapping strategy of searching
several electronic databases was used to identify potentially
relevant articles [21].
Time frame
A time frame was set and all entries between the years 1993-2009
were retrieved and analyzed. The final search of the databases
concluded at August 29th, 2009.
Searching strategy
Papers were retrieved using a double-filtration process. Firstly, a
subject filter selectively retrieved papers from the databases that
are relevant to the subfield. We used the following terms, burden
of illness, burden of disease, cost of illness, economic burden,
health burden, to seek matches in the titles, abstracts and MeSH
headings (Medline)/index term (EMBASE)/subjects (EconLit)/key-
words(Cochrane Library) of published articles. This was followed
by a geographical filter with names of the following 12 selected
AP countries and economic entities: Australia, China, Hong Kong,
India, Japan, Korea, Malaysia, New Zealand, Philippines, Singa-
pore, Taiwan, and Thailand, to select more subsets in the title,
abstract and MeSH headings/index term/subjects/keywords.
Non-English publications were also included in the searching
strategy. For the different searches, phrases were joined together
with Boolean operators ‘‘AND’’ and ‘‘OR’’.
The electronic search was supplemented by an second over-
lapping strategy where the reference lists of retrieved full articles
were searched manually to identify further relevant studies [21].
Culling criteria
Articles with English abstracts were included, as the aim was to
review all abstracts and classify the papers in various categories,
including type of paper, type of BOD indicator, main results,
disease covered and the country of origin of the study. When a
decision could not be reached based on information from the
abstract, full articles were retrieved and read to make the
decision. In the culling process, as our objective was to retrieve
original studies, therefore, reviews, manuscripts which only cite
BOD data as the supportive evidence, opinions, theory and
historical description articles were excluded. In addition, articles
were excluded if they focused mainly on intervention or pro-
grams controlling the BOD, validating instruments to measure
BOD or other topics that did not evaluate BOD itself. If the
abstract cannot provide enough information to make the judg-
ment for inclusion and exclusion, the full text article was
retrieved for further review.
Fig. 1 – Flow chart of articles selection process.
Table 1 – Classification of BOD studies.
Category Indicator Description Number
Partial
measures
Cost analyses not at population
level
134
Epidemiology 114
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For the identified articles, they were categorized according to the
scope of information provided by the study based on the outcome
measures used in each of the retrieved study. As a first cut, we
categorized all included studies in our current study into two main
types: BOD studies that provided full information and BOD studies
that provided partial information. Our definition of ‘‘full’’ informa-
tion refers to whether outcome measures used in the individual
study incorporate epidemiology, economic and humanistic burden
of the disease or condition being studied. Hence, BOD studies that
provide full information would be those using summary measures
to estimate the economic burden or humanistic burden of diseases
imposed on the patients or society in population level. The measure
indicators for BOD falling in this category include the COI study,
DALY, YHL and other summary Health-related Quality of Life
(HRQoL) indicators mentioned previously. Those COI studies which
combine information on prevalence or incidence with data on
resource use and costs are classified as providing ‘‘full’’ information.
Other studies were categorized as providing partial information if
the article was about burden on the caregiver only, not containing
epidemiological data to estimate in population level, or only
measuring one scope of BOD. Then the retrieved BOD studies were
further analyzed for publication time, country of origin, and disease
types. According to the International Monetary Fund’s (IMF) World
Economic Outlook Report 2010 [22], the countries were classified as
developed and emerging economies for subgroup analyses.Caregivers’ burden 58
Description of resource utilization
pattern
29
Quality of life measurement 29
Psychology measurement 15
Summary
measures
Cost-of-illness study 100
Summary indicator for humanistic
burden at population level (i.e.,
DALY, PPYLL)
45
BoD, burden of disease; DALY, Disability-adjusted life year; PPYLL,
Potential productivity years of life lost.Results
A total of 1432 articles were retrieved using overlapping search
strategy from four electronic databases. The manual search of
reference lists of retrieved full articles further identified 9 addi-
tional relevant articles. After the culling process, 524 articles
fulfilled the inclusion criteria and were further reviewed and
classified (Fig. 1).
Among the 524 BOD studies, 27.7% (n¼145) adopted summary
measures as indicator of BOD which would qualified them asproviding ‘‘full’’ information according to our study definition
(Table 1), with 100 estimated the COI and 45 evaluated human-
istic burden with summary indicators.
The geographic distribution of summary measures of BOD was
summarized in Fig. 2. Australia was the leading country in regards
to the number of both COI studies (n¼26) and partial estimations
(n¼85). In addition, Mainland China, Australia, and Korea had 13,
10 and 7 publications with summary humanistic burden estima-
tion respectively. These numbers are more than other countries
and regions. The number of full COI studies was less than 10 and
the studies using summary humanistic burden measures did not
exceed 3 in all other countries and regions. Even though some
countries, such as Japan and India, have relatively more publica-
tions for partial measures, they had less than 10 publications
adopting summary BOD measures.
To evaluate the chronological change of output quantitatively
we counted the BOD studies with summary measures and partial
measures separately in each year from 1993 to 2009 (Fig. 3). The
Fig. 2 – Geographic distribution of published BOD studies. BoD, burden of disease; COI, cost of illness.
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especially for COI studies. A gradual and quickening increase
from 2002 onwards was observed. Until the time of last retrieval,
the year 2008 had the largest amount of COI studies (n¼18) and
partial studies (n¼59). The year 2006 had the vast majority of the
summary humanistic burden studies (n¼7) published. The sub-
group analyses by economic status showed a more stable
increase of publications for summary measures in emerging than
developed economies since 2002 and the disparity of publication
numbers between them was gradually decreasing (Fig. 4). The
studies using partial measures had a similar increasing trend
since 2002 in both emerging and developed economies.
The breakdown of distribution pattern of BOD studies in each
of the 15 diseases/conditions is shown in Table 2 for COI,
summary humanistic burden measures and partial measures
separately. These 15 conditions are all conditions identified in
this review. Communicable diseases, neuro-psychiatric diseases,
and smoking/alcohol related conditions accounted for the three
largest groups of COI studies. Unlike the COI study identified in
this review, the number of the studies adopting summary
humanistic burden measures was much lower. Furthermore,
most of these studies are not disease specific and tend to providean overall picture of burden imposed by multiple diseases
concurrently. After multiple diseases coverage, injury and elderly
management, smoking and alcohol related conditions, and com-
municable diseases accounted for the three largest numbers of
articles with summary humanistic burden estimation. As for the
partial burden measurements, over 23% (n¼88) of them focussed
on communicable diseases. Except the caregiver burden, all other
partial measures were dominated by the communicable diseases.
Noticeably, some diseases areas, such as gastrointestinal, genito-
urinary, sensory organ and congenital anomalies had very poor
representation of the BOD for all measures. The subgroup
analyses show that research output in different disease areas
varied by economics status (Fig. 5). Most of the BOD studies in
emerging economies were devoted to communicable disease. In
contrast, the distribution of research output in different disease
areas was more evenly spread within developed economies.Discussion
This report summarized the recent research output of BOD
studies in AP region. Considering the merit of summary
Fig. 3 – Time distribution of published BOD studies. BoD, burden of disease; COI, cost of illness.
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allocation decision, we focused our analyses on the COI studies
and summary humanistic burden measures. Because of the lack
of clear definition for BOD studies, however, we also summarized
other measures for the burden of disease appeared in the
retrieved articles to provide a more comprehensive picture of
BOD studies carried out in this region. Partial measures identified
in this study included caregivers’ burden, description of resource
utilization pattern, psychological measurement, quality of life
measurement, cost analyses not at population level and epide-
miological studies. From the distribution of BOD studies, we
observed that the output of BOD studies is chronologically
increasing since 1993, and from 2002 the increase was quickened.
The volume of published research output was unbalanced among
different diseases/conditions or geographic areas for both sum-
mary and partial measures. The emerging economies showed a
more stable increase of publications in the recent years, espe-
cially those of summary measures, and had a greater apparent
research interest in communicable disease relative to developed
economies. This is understandable as communicable diseases are
more pressing concerns to the emerging economies. However,
some disease areas had very poor representation of the BOD
for all measures. Compared with partial estimation, comprehen-
sive estimation of BOD with summary measures are under-
researched because of the much higher demands in terms of
resources and expertise to carry out such studies.
The findings in this review highlight the lack of high quality
BOD studies among Asian countries. The lower outputs and
poorer quality of the study of BOD in Asian Pacific countries also
reflect the status of development in pharmacoeconomic researchand education in this region. To make amend of the situation,
guidelines and protocols as how to perform BOD studies based on
available data source would urgently be needed. A clear definition
about BOD is also necessary as the first step to develop standard
protocol. Furthermore, given the importance of BOD information
in setting health decision-making priority and for benchmarking
purpose across countries [3–7], more resources should be devoted
to this important but relatively neglected area.
To our best knowledge, the consensual definition of BOD study
is not available up to now. This might be a possible reason for the
wide variation of research scopes and perspectives identified in our
study. When referring to BOD, the researchers normally measure
the humanistic burden and economic burden. According to differ-
ent perspectives, however, such as the patients, the family/care-
giver, the health system, and the society, different indicators are
adopted. Nevertheless, from the perspective of policy decision
maker, estimating the BOD globally or at the country/region level
is necessary. Therefore, we classify the BOD studies into summary
measures and partial measures according to whether the estima-
tion is at population level or not. The size of the population affected
by the disease needs to be incorporated into the humanistic burden
and/or economic burden to produce a summary measure. Normally,
epidemiological data are used to reflect the size [3,12–16].
Even though the volumes of publications for summary BOD
estimation have increased since 1993, they are not commensu-
rate with the volume of diseases/conditions identified in our
study. This is especially noticeable in emerging economies where
most BOD studies were committed to communicable diseases.
Benchmarked against the list of diseases as presented by WHO
[23], BOD research output in AP region suggested that many
Fig. 4 – Time distribution of published BOD studies categorized by economic status of country. BoD, burden of disease; COI,
cost of illness.
Table 2 – Diseases distribution of published BOD study.
Summary Measure Partial Measure
Disease COI Humanistic Costs Epi Carer Resource QoL Psyco
Communicable 23 6 35 33 2 12 4 2
Neuro-psychiatric 13 2 5 5 13 2 0 3
Smoking and alcohol conditions 10 6 3 1 0 0 0 0
Cardiovascular 9 3 1 9 4 0 0 0
Injury and elderly management 8 8 11 7 14 2 4 1
Endocrine, nutritional & metabolic 7 1 10 12 0 0 2 0
Nervous 5 1 12 9 13 1 1 1
Respiratory 5 1 10 6 1 5 3 0
Sensory organ 5 0 9 1 0 0 1 0
Musculoskeletal system 4 3 8 5 0 1 4 1
Neoplasm 4 1 15 7 7 0 2 2
Gastrointestinal 3 0 4 1 0 5 3 2
Genitourinary 3 0 5 10 1 1 2 1
Congenital anomalies 1 1 1 4 0 0 0 2
Multiple diseases 0 12 5 4 3 0 3 0
Total 100 45 134 114 58 29 29 15
Carer, caregivers’ burden; COI, cost-of-illness study; costs, cost analyses not at population level; Epi, epidemiology; humanistic, summary
humanistic burden; psyco, psychology measurement; QOL, Quality of life measurement; resource, description of resource utilization pattern.
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Fig. 5 – Disease distribution of published BOD studies categorized by economic status of country. BoD, burden of disease.
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system disease, are not well estimated for their burden consid-
ering the high prevalence and the potential humanistic and
economic loss caused by them. Considering the wide variations
in socioeconomic and demographic features, the unbalance of
research output among different countries or regions within AP is
justifiable. Obviously, socioeconomic status, however, is not the
only determinant of volumes of publication. Even in Australia
with more public health research articles identified than other
developing country [24], the number of summary BOD estimation
is limited, especially for the summary humanistic burden esti-
mation. In most of studied countries and regions, the number of
COI studies outweighed summary humanistic burden estimation.
Furthermore, the main problem of COI studies is that most of the
COI estimations were not from societal perspective, thus decreas-
ing the informative power of this potentially comprehensive
indicator. In our study, 50% of the COI studies (51 articles)
estimated indirect cost and only 2% (2 articles) took intangible
cost into account. Theoretically, intangible cost measurement is a
practical way to translate patients’ pain and discomfort into
monetary terms and, in many cases, this component is substan-
tial and might dominate the policy agenda. Because of the
complexities and unresolved theoretical controversies in meas-
uring intangible cost, however, it is seldom considered in COI
estimation [25]. The two COI studies identified here measured
intangible cost using willingness-to-pay method [26] and utility
score times estimated value of life [27] respectively. Actually, the
lack of an accepted method to provide a uniform template for the
cost estimation may limit the reliability and validity of COI study
in the decision making process.
In our study, we tracked the output of original BOD research in
AP region for guiding further appropriate development of
research. However, it must be noted that research publications
may not accurately reflect all outputs in the studied regions. Forexample, government reports about BOD estimation from Aus-
tralia Institute of Health and Welfare (http://www.aihw.gov.au)
are not included in current searching databases. Nevertheless, for
most of other countries and regions in AP, we were unable to
locate similar reports on the government websites. In addition,
some of the government reports are republished in the peer-
reviewed journals. So, with the aforementioned caveats, overall,
our review would be a reasonable representation of the status of
research in the AP region.Conclusion
In order to use BOD estimation at the country/region level to
guide priority setting in public health decision making, and in
assessing the performance of health care system over time, data
availability is an important starting point for future strategic
planning, however, estimating BOD comprehensively is a com-
plex task and the paucity of specific studies in most AP countries/
regions needs to be addressed. In order to improve the quality of
research, a clear definition of BOD studies and a uniform
template of research method from health policy-makers’ per-
spective would be necessary.
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